Horowitz RI et al., 2024-04-30: Case series of three patients with chronic Lyme disease given multi-drug pulsed regimens that included methylene blue, reporting improvement in resistant fatigue and other symptoms; methylene blue was never given alone.
short-term pulsed biofilm/persister drug combination therapy i.e., dapsone, rifampin, methylene blue, and pyrazinamide, which improved resistant fatigue, pain, headaches, insomnia, and neuropsychiatric symptoms
abstract
Horowitz RI et al., 2024-04-30: Case series of three patients with chronic Lyme disease given multi-drug pulsed regimens that included methylene blue, reporting improvement in resistant fatigue and other symptoms; methylene blue was never given alone. Study type: case series (3 patients) plus literature review. N=3. Country: USA (Hudson Valley Healing Arts Center). Methylene blue dose, route, schedule and duration: not stated in the abstract; MB was one component of a four-drug pulse (dapsone, rifampin, methylene blue, pyrazinamide) alongside antimalarials and herbal therapy. Comparator: none (before-after, patient report). Funder: not stated; declared conflicts: none. Cannot be used to attribute any fatigue benefit to methylene blue alone. Patients had Lyme disease, not CFS, long COVID or fibromyalgia by name.
